Press Releases

Date Title  
Feb 27, 2020
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET -
Feb 26, 2020
CAMBRIDGE, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming investor
Feb 21, 2020
CAMBRIDGE, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2019 financial
Feb 6, 2020
- Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TIS vopra ) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit in patients from the ICONIC trial - - Research collaboration established with NanoString to
Jan 23, 2020
CAMBRIDGE, Mass. , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Robert Iannone , M.D., M.S.C.E., to its
Jan 9, 2020
CAMBRIDGE, Mass. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray , Ph.D., chief executive officer and